GlassScriptPhysician profile
Subroto Gangopadhyay
NPI 1346206174
$1,631.33
in general payments reported to CMS, 2019-2025
17 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.57 · 2020: $19.83 · 2021: $44.44 · 2022: $373 · 2023: $253 · 2024: $547 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $392.46 | 2019-2025 | Watchman Access System, Ekosonic, Watchman Flx |
| Janssen Pharmaceuticals, INC | $210.55 | 2022-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $201.38 | 2022-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $178.00 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $147.60 | 2019-2022 | |
| Pfizer INC. | $130.15 | 2023-2025 | |
| Abbott Laboratories | $98.88 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals International, Plc | $73.17 | 2024 | Arcalyst |
| Amgen INC. | $34.09 | 2023-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $32.87 | 2025 | Eliquis |
| Heartflow, INC. | $30.66 | 2025 | |
| Inspire Medical Systems, INC. | $23.09 | 2023 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $22.19 | 2023 | Arcalyst |
| Althera Pharmaceuticals LLC | $15.16 | 2022 | |
| Agepha Pharma Fz LLC | $14.52 | 2024 | Lodoco |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $13.60 | 2024 | Sapien 3 Ultra Resilia |
| Cashflow Solutions, LLC | $12.96 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subroto Gangopadhyay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.